Compounded Tirzepatide Safety Alert: Adverse Events, a New Impurity, and Counterfeits (2026)

Where the risk concentrates

Two patterns dominate the reports. The first is dosing errors: much compounded tirzepatide ships as a multi-dose vial with syringes, so the patient must draw the correct units each week. Measuring in the wrong units, using the wrong concentration, or misreading a titration change can lead to injecting several times the intended dose, and some of these errors required hospitalization. The second is product-quality issues from unverified sourcing, including impurities and counterfeits.

Adverse-event reports (as of early 2025)

Safety signals summarized

How dosing errors happen with vials

Most FDA-approved tirzepatide comes in prefilled, fixed-dose pens. Multi-dose vials shift the measurement burden to the patient, which is precisely where many reported errors occur. Prefilled, single-dose delivery is designed to eliminate this failure mode, which is one practical safety argument for approved products where a patient can access them.

What FDA-approved products avoid

Approved Mounjaro and Zepbound are manufactured under strict quality controls, carry verified concentration and labeling, and move through channels that make counterfeiting far harder. They are not implicated in the impurity and counterfeit findings above, which involve compounded or gray-market supply. That difference — verified identity, strength, and sourcing — is the core safety distinction.

How to protect yourself

Where possible, choose FDA-approved products. If you use compounded medicine under a documented clinical need, verify the pharmacy pathway, request a certificate of analysis, confirm concentration and fill volume, and never self-adjust a vial dose without clinician guidance. See our side-effects management guide. This is a sensitive area; if a product seems off, do not use it and contact a licensed clinician or pharmacist.

What regulators are doing

The safety signals sit alongside a broader regulatory tightening. The FDA has issued warning letters over misleading marketing and salt-form active ingredients, cited outsourcing facilities for sterility and labeling problems, and proposed permanently excluding tirzepatide from the 503B bulks list. Together these actions push the market toward documented, patient-specific compounding and FDA-approved products, and away from the mass-market vials most associated with the adverse-event reports. For patients, that trend reinforces the same practical advice: verify sourcing and prefer verified, approved options where you can.

Questions to ask your provider

Before starting or continuing a compounded program, ask a few plain questions: Which pharmacy compounds my medication, and is it a 503A pharmacy or a 503B outsourcing facility? Is the active ingredient the base peptide rather than a salt form? Can you provide a certificate of analysis, and what are the concentration and fill volume so I can dose accurately? How do you document the clinical basis for my prescription? A provider that answers these clearly is demonstrating the transparency that separates careful operators from the ones behind the safety reports.

Frequently asked questions

How many adverse events have been reported?

As of early 2025, 455+ reports tied to compounded semaglutide and 320+ tied to compounded tirzepatide, many involving dosing errors from multi-dose vials.

What is the tirzepatide-B12 impurity?

A March 2026 analysis identified a tirzepatide-B12 adduct in some mass-compounded tirzepatide-with-B12 products — a compound not present in FDA-approved tirzepatide, with unknown safety.

Are counterfeits a real risk?

Yes. The FDA has documented counterfeit and falsely labeled tirzepatide entering the market through online channels.

How do I lower my risk?

Prefer FDA-approved products where possible; if using compounded medicine, verify the pharmacy pathway, request certificates of analysis, and never self-adjust doses.